All News
This work can lay foundation to so much more!
#ArtificialIntelligence and #naturallanguageprocessing on Facebook private #gout groups
- Mental health mentioned in 4% of all posts/comments
- primary care asso with “trust” and urgent care with “fear”
@RheumNow #ACR22 abst#0201 https://t.co/fSuOeNGWvg
Bella Mehta bella_mehta ( View Tweet)
Botson et al. 52 week results MIRROR trial. MTX added to pegloticase. 71% vs 39% SU <6mg/dl. Infusion reaction 13% vs 32% if ab+ 0% vs 30% ab- @RheumNow #ACR22 Abstr#0001 #ACRbest https://t.co/1c3Va9NxNX https://t.co/dPGDyWue4G
Richard Conway RichardPAConway ( View Tweet)
Black study subjects remain underrepresented in rheumatology clinical trials except for gout. Abs 0089
Continued under-reporting of race and ethnicity in PsA trials. Abs 0090
We can do better #rheumtwitter
#ACR22 @RheumNow https://t.co/lzFXxFxgNs and https://t.co/K9dYaaXCg8 https://t.co/VqQe1OCsKg
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary 1. Abstr#0001 Another important use of #methotrexate. MIRROR RCT showed greater response in pegloticase + MTX vs pegloticase + PBO and lower infusion reaction. Be interesting to define MTX dose and ?other DMARDs esp in patients with CKD @RheumNow #ACRBest https://t.co/xkP6ZZGQfu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abst#0001 MIRROR RCT at #ACR22 #plenary
Pts with gout on #pegloticase and #gout
sustained higher urate lowering response in pts cotreated with #MTX
benefit beyond 6 months
@rheumnow https://t.co/rTZ3fPaFJS
Bella Mehta bella_mehta ( View Tweet)
🪞MIRROR RCT🪞
💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%)
🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻)
🧪⬇️ drug Ab with MTX
✅ No new IRs
Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC
Patricia Harkins DrTrishHarkins ( View Tweet)
Excellent start to the first plenary session!
MIRROR study - MTX coadministration with pegloticase for gout treatment
- doubling of efficacy and 7x decrease in infusion reactions
- less anti-PEG abs
@RheumNow #ACR22 Abs#0001 https://t.co/V1HIYypmpO
Robert B Chao, MD doctorRBC ( View Tweet)
MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4
Dr. Rachel Tate uptoTate ( View Tweet)
Role of acquired mutations in #gout
Risk factor for gout CHIP?
Individuals with CHIP are more likely to developed acute episodes of gouty episodes
More IL-1B in cells with somatic mutations like CHIP
@rheumnow #ACR22 #yearinreview https://t.co/k3VeZuTCln
Bella Mehta bella_mehta ( View Tweet)
CHIP- need to know! Somatic mutations fondly known as CHIP - not the salty ones. Clonal hematopoeisis of uncertain significance. Older Pts getting somatic mutations account for more CVS, malignancies , one change in TET2 increased gout #ACR2022 @RheumNow John Barga Yr in Review https://t.co/6bnqnkDFpL
Janet Pope Janetbirdope ( View Tweet)
MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia...
@RheumNow #ACR22 #yearinreview
Julian Segan JulianSegan ( View Tweet)
Year in Review
#ACR22
Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies
@RheumNow https://t.co/EPtOrjJqLd
Eric Dein ericdeinmd ( View Tweet)
Preview of what is sure to be discussed more in detail later..
MIRROR trial of MTX co-administration with pegloticase in treatment of gout.
MTX co-administration improved control of gout, reduced infusion reactions
@RheumNow #ACR22 https://t.co/r0MEq1rkgO
Robert B Chao, MD doctorRBC ( View Tweet)
Population study shows among vaccinated gout pts, COVID breakthrough infection occurred in @ 4.68/1K Pt-mos vs 3.76/1K Pt-mos in non-Gout persons. Gout w/ Covid had More Hosp (aHR=1.30) & death (aHR=1.36), moreso in Women w/ gout (aHR 1.55 & 2.46) https://t.co/ViwiPzqTbZ https://t.co/BrXd6pbgRI
Links:
Dr. John Cush RheumNow ( View Tweet)
Single center study from UAB shows 72 gout pts treated & D/C from ED were Rx w/ steroids (64%), opioids (63%), NSAIDs (43%), colchicine (32%). But only 26/72 (36%) had subsequent outpatient clinic visit for gout. https://t.co/I8jjqIqJXd https://t.co/05YSibd6iz
Links:
Dr. John Cush RheumNow ( View Tweet)
Will we see you there? #ACR2022
What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow ( View Tweet)
#Gout clinic study of 223 gout pts on allopurinol ≥300 mg compared Pt & MD gout control assessments (0-10). Better agreement & higher scores seen w/o flares (3 or 12 mos) & SUA w/in target. Disagreement (22%) w/ recent flares & tophi https://t.co/a0WsMLvfYk https://t.co/zZwV4XVJzS
Links:
Dr. John Cush RheumNow ( View Tweet)
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM
Dr. John Cush RheumNow ( View Tweet)
Top Tweet of September:
Gout: diagnosis and management—summary of NICE guidance
https://t.co/CWg4otNBVv https://t.co/wRcjnC59eL
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Salaries and Career Choices
A recent Doximity report shows how rheumatology salaries increase by years in practice. Rheumatologists tend to earn their highest salaries after gaining 30-39 years of experience.
https://t.co/wxWQruIlu9 https://t.co/gUsIffoHn6
Links:
Dr. John Cush RheumNow ( View Tweet)
